471 related articles for article (PubMed ID: 31218661)
1. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
[TBL] [Abstract][Full Text] [Related]
2. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Thaci D; Piaserico S; Warren RB; Gupta AK; Cantrell W; Draelos Z; Foley P; Igarashi A; Langley RG; Asahina A; Young M; Falqués M; Pau-Charles I; Mendelsohn AM; Rozzo SJ; Reich K
Br J Dermatol; 2021 Aug; 185(2):323-334. PubMed ID: 33544883
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
Kimball AB; Papp KA; Reich K; Gooderham M; Li Q; Cichanowitz N; La Rosa C; Blauvelt A
Br J Dermatol; 2020 Jun; 182(6):1359-1368. PubMed ID: 31487406
[TBL] [Abstract][Full Text] [Related]
4. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
[TBL] [Abstract][Full Text] [Related]
7. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Elewski B; Menter A; Crowley J; Tyring S; Zhao Y; Lowry S; Rozzo S; Mendelsohn AM; Parno J; Gordon K
J Dermatolog Treat; 2020 Dec; 31(8):763-768. PubMed ID: 31268369
[No Abstract] [Full Text] [Related]
8. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
[TBL] [Abstract][Full Text] [Related]
9. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
Lebwohl MG; Leonardi CL; Mehta NN; Gottlieb AB; Mendelsohn AM; Parno J; Rozzo SJ; Menter MA
J Am Acad Dermatol; 2021 Feb; 84(2):398-407. PubMed ID: 32961255
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.
Poulin Y; Ramon M; Rosoph L; Weisman J; Mendelsohn AM; Parno J; Rozzo SJ; Lee P
J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1500-1509. PubMed ID: 31919889
[TBL] [Abstract][Full Text] [Related]
11. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Fernandez AP; Dauden E; Gerdes S; Lebwohl MG; Menter MA; Leonardi CL; Gooderham M; Gebauer K; Tada Y; Lacour JP; Bianchi L; Egeberg A; Pau-Charles I; Mendelsohn AM; Rozzo SJ; Mehta NN
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1774-1783. PubMed ID: 35460287
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies.
Thaçi D; Gerdes S; Du Jardin KG; Perrot JL; Puig L
Dermatol Ther (Heidelb); 2022 Oct; 12(10):2325-2341. PubMed ID: 36098877
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.
Ter Haar ELM; Van den Reek JMPA; Gaarn Du Jardin K; Barbero-Castillo A; De Jong EMGJ; Lubeek SFK
Acta Derm Venereol; 2023 Oct; 103():adv17752. PubMed ID: 37877618
[TBL] [Abstract][Full Text] [Related]
14. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
15. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.
Warren RB; Carrascosa JM; Fumero E; Schoenenberger A; Lebwohl MG; Szepietowski JC; Reich K
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):919-927. PubMed ID: 32979235
[TBL] [Abstract][Full Text] [Related]
16. Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest.
Egeberg A; Jullien D; Gaarn Du Jardin K; Thaçi D
J Dermatolog Treat; 2023 Dec; 34(1):2220447. PubMed ID: 37341303
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Feldman SR; Merola JF; Pariser DM; Zhang J; Zhao Y; Mendelsohn AM; Gottlieb AB
J Dermatolog Treat; 2022 May; 33(3):1670-1675. PubMed ID: 33678106
[TBL] [Abstract][Full Text] [Related]
18. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
[TBL] [Abstract][Full Text] [Related]
19. Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.
Yu C; Geng S; Yang B; Deng Y; Li F; Kang X; Bi M; Zhang F; Zhao Y; Pan W; Tian Z; Xu J; Zhang Z; Yu N; Duan X; Guo S; Sun Q; Li W; Tao J; Liu Z; Yin Y; Wang G
Chin Med J (Engl); 2024 May; 137(10):1190-1198. PubMed ID: 38192233
[TBL] [Abstract][Full Text] [Related]
20. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
